These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2439824)

  • 1. Withdrawal of the long-acting beta blocker bopindolol is not associated with beta-adrenoceptor supersensitivity.
    Bolli P; Amann FW; Müller FB; Meyer B; Burckhardt D; Bühler FR
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S64-9. PubMed ID: 2439824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol.
    Bolli P; Bühler FR; Raeder EA; Amann FW; Meier M; Rogg H; Burckhardt D
    Circulation; 1981 Dec; 64(6):1130-4. PubMed ID: 6117379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.
    van Brummelen P; Bühler FR; Amann FW; Bolli P
    Eur J Clin Pharmacol; 1982; 22(6):491-3. PubMed ID: 6127218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacological studies with the long-acting beta-adrenoceptor blocking drug bopindolol.
    Aellig WH
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S12-5. PubMed ID: 2439811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age.
    Hulthén UL; van Brummelen P; Amann FW; Bühler FR
    J Cardiovasc Pharmacol; 1983; 5(3):426-9. PubMed ID: 6191141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bopindolol: long-term effects on blood pressure, renal function, plasma renin activity, and plasma aldosterone in mild-to-moderate essential hypertension.
    Shohat J; Modan M; Rosenfeld JB
    Fundam Clin Pharmacol; 1989; 3(1):53-8. PubMed ID: 2565862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal phenomena after atenolol and bopindolol: hormonal changes in normal volunteers.
    Walden RJ; Tomlinson B; Graham B; Smith C; Betteridge DJ; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):547-56. PubMed ID: 1981317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bopindolol, a new long-acting beta-adrenoceptor antagonist--a randomized comparison against propranolol in hypertensive patients.
    Kirch W; Axthelm T
    Int J Clin Pharmacol Res; 1983; 3(2):89-93. PubMed ID: 6148312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.
    Brodde OE; Wang XL; O'Hara N; Daul A; Schiess W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S70-3. PubMed ID: 2439825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bopindolol on renin secretion and renal excretory function in rats.
    Proakis AG; Barrett RJ; Anderson LA; Wright KF; Taylor DR
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):862-9. PubMed ID: 2484080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and long-term antihypertensive effect of bopindolol--a nonselective beta-adrenergic blocker with ISA.
    Andersson OK; Hedner T; Nyberg G
    Eur J Clin Pharmacol; 1985; 29(3):281-5. PubMed ID: 2866965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.
    Schiess W; Dorow P
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S30-3. PubMed ID: 2439815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical pharmacology of bopindolol, a new long-acting beta-adrenoceptor antagonist, in hypertension.
    van den Meiracker AH; Man in 't Veld AJ; van Eck HJ; Boomsma F; Derkx FH; Mulder P; Schalekamp MA
    Clin Pharmacol Ther; 1987 Oct; 42(4):411-9. PubMed ID: 2889554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers.
    Walden RJ; Tomlinson B; Graham B; Liu JB; Prichard BN
    Br J Clin Pharmacol; 1990 Oct; 30(4):557-65. PubMed ID: 1981318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bopindolol on renal function.
    Fabre J; Wintsch J; Peter-Contesse R; Bouchardy C; Liniger C; Favre L; Donath A
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S45-50. PubMed ID: 2439819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute and long-term antihypertensive effect of bopindolol once daily or once weekly.
    Andersson O; Hedner T; Nyberg G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S74-6. PubMed ID: 2439826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.
    Schiess W; Welzel D; Gugler R
    Eur J Clin Pharmacol; 1984; 27(5):529-34. PubMed ID: 6151506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.
    Aellig WH
    Br J Clin Pharmacol; 1985 Jun; 19(6):775-81. PubMed ID: 2862891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.